Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Solar storms have influenced our history – an environmental historian explains how they could also threaten our future - 2Tech giants accused of not complying with Australian social media ban
- 3Best Getaway destination: Ocean side, Mountain, or City
- 4The Best Internet based Courses for Expertise Improvement
- 5Must-See Attractions in Australia
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
- The Most Paramount Crossroads in Olympic History
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- Brazil approves law strengthening protective measures for female victims of gender-based violence
- Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
- Ukraine confirms defence and energy ministers at second attempt
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- ByHeart sued over recalled formula by parents of infants sickened with botulism
